PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment.

ABSTRACT: Severe asthma accounts for almost half the cost associated with asthma. Severe asthma is driven by heterogeneous molecular mechanisms. Conventional clinical trial design often lacks the power and efficiency to target subgroups with specific pathobiological mechanisms. Furthermore, the validation and approval of new asthma therapies is a lengthy process. A large proportion of that time is taken by clinical trials to validate asthma interventions. The National Institutes of Health Precision Medicine in Severe and/or Exacerbation Prone Asthma (PrecISE) program was established with the goal of designing and executing a trial that uses adaptive design techniques to rapidly evaluate novel interventions in biomarker-defined subgroups of severe asthma, while seeking to refine these biomarker subgr

SUBMITTER: Israel E 

PROVIDER: S-EPMC8113113 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature